Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Memed Diagnostics Ltd. operates a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 3 pending office actions. These actions are distributed among 3 distinct examiners, meaning each examiner is currently reviewing 1 application or matter.
The prosecution spans 2 distinct art units. This distribution indicates that while the technology remains within Biotechnology & Pharmaceuticals, the specific claims are categorized into 2 different specialized units at the USPTO. Kristina Elisabeth Ly is identified as the busiest examiner for this portfolio, with 1 pending office action currently under her review.
With 3 pending office actions and 3 distinct examiners, the company manages 3 separate examiner relationships. The 2 distinct art units suggest that the legal strategy may need to be tailored to the specific nuances of each unit, even though the busiest examiner, Kristina Elisabeth Ly, only handles 1 of the 3 pending actions. This spread of 3 examiners for 3 actions ensures that no single examiner handles more than 1 pending matter for the company.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LY, KRISTINA ELISABETH | 1 | 37.5% | +100.0% |
| PARKIN, JEFFREY S | 1 | 63.7% | +21.7% |
| QIAN, CELINE X | 1 | 47.6% | +16.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18272838 | MARKERS FOR DIAGNOSING INFECTIONS | LY, KRISTINA ELISABETH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17796284 | METHODS OF DIAGNOSING AND CLASSIFYING VIRAL INFECTIONS | QIAN, CELINE X | 14d |
| 17955599 | RNA DETERMINANTS FOR DISTINGUISHING BETWEEN BACTERIAL AND VIRAL INFECTIONS | PARKIN, JEFFREY S | 28d |
| 18272838 | MARKERS FOR DIAGNOSING INFECTIONS | LY, KRISTINA ELISABETH | — |
| Art Unit | Apps |
|---|---|
| 1671 | 2 |
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18272838 | MARKERS FOR DIAGNOSING INFECTIONS | LY, KRISTINA ELISABETH | 1671 | §103§112 | Non-Final OA | — | Pending | Jul 18, 2023 |
| 17955599 | RNA DETERMINANTS FOR DISTINGUISHING BETWEEN BACTERIAL AND VIRAL INFECTIONS | PARKIN, JEFFREY S | 1671 | §112 | Non-Final OA | 28d | Pending | Sep 29, 2022 |
| 17796284 | METHODS OF DIAGNOSING AND CLASSIFYING VIRAL INFECTIONS | QIAN, CELINE X | 1637 | §103 | Non-Final OA | 14d | Pending | Jul 29, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial